Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Int J Technol Assess Health Care ; 30(2): 147-52, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24774034

RESUMO

OBJECTIVES: The aim of this study was to assist in the development of a health technology assessment (HTA) program for the Ministry of Health (MOH) of the Republic of Kazakhstan METHODS: Mentoring of an initial HTA program in Kazakhstan was provided by the Canadian Society for International Health (CSIH) by means of a partnership with the Kazakhstan MOH. HTA materials, courses, and one-on-one support for the preparation of a series of initial HTA reports by MOH HTA staff were provided by a seven-member CSIH team over a 2.5-year project. RESULTS: Guidance documents on HTA and institutional strengthening were prepared in response to an extensive set of deliverables developed by the MOH and the World Bank. Introductory and train-the-trainer workshops in HTA and economic evaluation were provided for MOH staff members, experts from Kazakhstan research institutes and physicians. Five short HTA reports were successfully developed by staff in the Ministry's HTA Unit with assistance from the CSIH team. Challenges that may be relevant to other emerging HTA programs included lack of familiarity with some essential underlying concepts, organization culture, and limited time for MOH staff to do HTA work. CONCLUSIONS: The project helped to define the need for HTA and mentored MOH staff in taking the first steps to establish a program to support health policy decision making in Kazakhstan. This experience offers practical lessons for other emerging HTA programs, although these should be tailored to the specific context.


Assuntos
Desenvolvimento de Programas , Avaliação da Tecnologia Biomédica , Saúde Global , Política de Saúde , Cazaquistão
2.
Pharmacoeconomics ; 23(2): 143-53, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-15748089

RESUMO

BACKGROUND: Despite the considerable amount of work that has gone into the standardisation of costs, a recent survey indicated that there is still a wide variation in methods used in costing studies in the published literature. Part of the answer to the lack of standardisation may lie in pharmacoeconomic guidelines themselves. OBJECTIVE: The purpose of this paper is to categorise the current recommendations for the analysis of costs within an economic evaluation, and to use these categories to assess variations in guidelines. DESIGN: Based on identified costing methodology, we developed a detailed categorisation. We then surveyed existing guidelines to determine similarities and differences in the guidelines. RESULTS: Our framework had five categories: general design items; resource identification and classification; resource measurement; resource valuation; and overall reporting. We noted differences in perspective, some of which were due to methodological uncertainty and differences in the purposes of the studies covered by the guidelines. There was very little guidance in how to put the basic cost measure into operation. In addition, the preferred concept for resource utilisation was that of resource use under actual (rather than experimental) conditions, and there was very little guidance as to how to achieve this measure. CONCLUSION: There are still large variations, as well as gaps, in guidelines in the costing area. This is due, in part, to wide-ranging objectives for studies, methodological uncertainty and a neglect of the fundamentals of costing. We recommend that the contents of the basic measure of 'average cost' should be explained in more detail, with recurring, capital and allocated overhead costs being reported separately. A target capacity level (e.g. 80%) should be reported, even if in a sensitivity analysis. More guidance should be provided regarding the translation of utilisation under experimental care to that under routine care. For resource valuation, adjustments to the 'average cost' measure should be made explicit. There should be more guidance on how to project system-wide costs from the costs of one hospital. The manner in which overall results are reported should be addressed, including the identification of how costs should be categorised.


Assuntos
Custos e Análise de Custo , Farmacoeconomia , Guias como Assunto , Custos de Cuidados de Saúde , Humanos
3.
Artigo em Inglês | MEDLINE | ID: mdl-15736510

RESUMO

OBJECTIVES: Given the resource-intensive nature of stroke rehabilitation, it is important that services be delivered in an evidence-based and cost-efficient manner. The objective of this review was to assess the evidence on the relative cost or cost-effectiveness of three rehabilitation services after stroke: stroke unit care versus care on another hospital ward, early supported discharge (ESD) services versus "usual care," and community or home-based rehabilitation versus "usual care." METHODS: A systematic literature review of cost analyses or economic evaluations was performed. Study characteristics and results (including mean total cost per patient) were summarized. The level of evidence concerning relative cost or cost-effectiveness for each service type was determined qualitatively. RESULTS: Fifteen studies met the inclusion criteria: three on stroke unit care, eight on ESD services, and four on community-based rehabilitation. All were classified as cost-consequences analysis or cost analysis. The time horizon was generally short (1 year or less). The comparators and the scope of costs varied between studies. CONCLUSIONS: There was "some" evidence that the mean total cost per patient of rehabilitation in a stroke unit is comparable to care provided in another hospital ward. There is "moderate" evidence that ESD services provide care at modestly lower total costs than usual care for stroke patients with mild or moderate disability. There was "insufficient" evidence concerning the cost of community-based rehabilitation compared with usual care. Several methodological problems were encountered when analyzing the economic evidence.


Assuntos
Serviços de Assistência Domiciliar/economia , Centros de Reabilitação/economia , Reabilitação do Acidente Vascular Cerebral , Acidente Vascular Cerebral/economia , Análise Custo-Benefício , Custos e Análise de Custo , Política de Saúde/economia , Humanos
4.
Issues Emerg Health Technol ; (44): 1-6, 2003 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-12653112

RESUMO

Vacuum assisted closure (VAC) therapy is designed to promote the formation of granulation tissue for faster healing in the wound beds of patients with acute and chronic wounds. Four controlled trials and one interim analysis provide poor quality data and weak evidence that VAC therapy may be superior to conventional methods used in healing wounds. Complications with VAC therapy are uncommon. Studies are needed to evaluate the effectiveness of VAC therapy when the types of dressings are the same for patients in the groups being compared and VAC therapy is the only differing intervention.


Assuntos
Bandagens , Vácuo , Cicatrização/fisiologia , Ferimentos e Lesões/terapia , Bandagens/efeitos adversos , Bandagens/economia , Canadá , Contraindicações , Análise Custo-Benefício , Aprovação de Equipamentos , Difusão de Inovações , Humanos , Ensaios Clínicos Controlados Aleatórios como Assunto , Higiene da Pele , Resultado do Tratamento , Estados Unidos , United States Food and Drug Administration
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA